Blood Inflammatory Molecules Increased in ALS
By LabMedica International staff writers Posted on 06 Sep 2017 |
Image: Chronic neuro-inflammation as measured by high levels of circulating inflammatory cytokines and activated astrocytes and microglia in the brain (Photo courtesy of Dr. Oksana Kaidanovich-Beilin et al).
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a fatal neurodegenerative disease characterized by the degeneration of motor neurons in brain and spinal cord. Only 5% to 10% of ALS cases are explained by a genetic mutation, while 90% to 95% of cases are sporadic, with no known cause.
A growing number of studies indicate that inflammation in the central nervous system is a key factor in ALS and additionally, increased levels of immune cells that trigger inflammatory responses have been found in the central nervous system of ALS patients. Clinical studies indicated that peripheral inflammation is involved in ALS, where markers of inflammation such as T-cells, cytokines, and chemokines were found.
Scientists at Minzu University of China (Beijing, China) performed a systematic review and meta-analysis that identified 25 studies, including 812 ALS patients and 639 controls. This was done in order to address inconsistent results, so they compared levels of inflammatory cytokines between ALS patients and controls. The clinical data information was then combined and analyzed.
The meta-analysis found significant heterogeneity for eight of 14 cytokines. Interleukin (IL)-2, IL-4, IL-17, vascular endothelial growth factor (VEGF) showed moderate levels of heterogeneity, whereas tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), interferon gamma (IFNγ), IL-5 showed high levels of heterogeneity. Sub-group analyses revealed that blood TNF-α levels were significantly increased in ALS patients compared with normal control subjects.
The scientists noted that previous data demonstrated that blood levels of TNF-α, IL-6 and IL-1β were elevated in patients with Alzheimer’s disease and Parkinson’s disease, while Tumor necrosis factor receptor 1(TNFR1) was augmented in Parkinson’s disease, suggesting a common mechanism in different neurodegenerative disorders.
The authors concluded that, their meta-analysis is the first undertaken to investigate the alterations of inflammatory cytokine levels in ALS patients, and demonstrated increased peripheral blood TNF-α, TNFR1, IL-1β, IL-6, IL-8 and VEGF levels in ALS patients compared to control subjects. The study highlights the possibility that peripheral levels of cytokines could be biomarkers for ALS, which would offer an attractive approach for medical professionals seeking to bridge the gap between diagnosis and onset of symptoms. The study was published on August 22, 2017, in the journal Scientific Reports.
Related Links:
Minzu University of China
A growing number of studies indicate that inflammation in the central nervous system is a key factor in ALS and additionally, increased levels of immune cells that trigger inflammatory responses have been found in the central nervous system of ALS patients. Clinical studies indicated that peripheral inflammation is involved in ALS, where markers of inflammation such as T-cells, cytokines, and chemokines were found.
Scientists at Minzu University of China (Beijing, China) performed a systematic review and meta-analysis that identified 25 studies, including 812 ALS patients and 639 controls. This was done in order to address inconsistent results, so they compared levels of inflammatory cytokines between ALS patients and controls. The clinical data information was then combined and analyzed.
The meta-analysis found significant heterogeneity for eight of 14 cytokines. Interleukin (IL)-2, IL-4, IL-17, vascular endothelial growth factor (VEGF) showed moderate levels of heterogeneity, whereas tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), interferon gamma (IFNγ), IL-5 showed high levels of heterogeneity. Sub-group analyses revealed that blood TNF-α levels were significantly increased in ALS patients compared with normal control subjects.
The scientists noted that previous data demonstrated that blood levels of TNF-α, IL-6 and IL-1β were elevated in patients with Alzheimer’s disease and Parkinson’s disease, while Tumor necrosis factor receptor 1(TNFR1) was augmented in Parkinson’s disease, suggesting a common mechanism in different neurodegenerative disorders.
The authors concluded that, their meta-analysis is the first undertaken to investigate the alterations of inflammatory cytokine levels in ALS patients, and demonstrated increased peripheral blood TNF-α, TNFR1, IL-1β, IL-6, IL-8 and VEGF levels in ALS patients compared to control subjects. The study highlights the possibility that peripheral levels of cytokines could be biomarkers for ALS, which would offer an attractive approach for medical professionals seeking to bridge the gap between diagnosis and onset of symptoms. The study was published on August 22, 2017, in the journal Scientific Reports.
Related Links:
Minzu University of China
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms